Bernstein’s $11.9 target on SMMT

SMMT Summit Therapeutics

$17.3 → $11.9 (-31%) by Oct 2027

Market Perform · reiterates · said Oct 5, 2026 · 12-month default horizon

Open: judged on the close on Oct 5, 2027

The article this target came from

Bernstein reiterates Summit Therapeutics stock rating on trial concerns

Investing.com · Oct 5, 2026

Bernstein reiterates Summit Therapeutics stock rating on trial concerns

Bernstein’s track record → Summit Therapeutics →

A fact about what Bernstein published, as reported by Investing.com, not a recommendation from Dalsna Finance; Bernstein is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.